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Prognostic role of clinical, pathological and biological
characteristics in patients with locally advanced breast
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Summary Forty-two patients with clinical stage IIIA or IIIB breast cancer were treated with neoadjuvant chemotherapy followed by
mastectomy and radiotherapy. The median follow-up was 32 months (range 10-72 months) and the median time to progression was 17
months (range 10-30 months). A multivariate analysis showed that a longer disease-free survival (DFS) was related to more chemotherapy
cycles given (P = 0.003), a better pathological response to chemotherapy (P = 0.04) and fewer positive axillary lymph nodes (P = 0.05). A
better overall survival (OS) was related to more chemotherapy cycles given (P = 0.03) and better pathological response to chemotherapy
(P= 0.04). In patients with residual tumour after neoadjuvant chemotherapy, high levels of staining for Ki-67 was correlated with a worse DFS
(P= 0.008). Other biological characteristics, including oestrogen receptor status, microvessel density (CD31 staining), P-glycoprotein (P-gp)
staining and nuclear accumulation of p53, were not independent prognostic factors for either DFS or OS. If both P-gp and p53 were
expressed, DFS and OS were worse in the uni- and multivariate analysis. The preliminary results of this phase 11 study suggest that
coexpression of P-gp/p53 and a high level of staining for Ki-67 afterchemotherapy are associated with a worse prognosis, and that prolonged
neoadjuvant chemotherapy and the attainment of a pathological complete remission are important factors in determining outcome for patients
with this disease.
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Neoadjuvant chemotherapy followed by either radiotherapy,
surgery orboth has improved the prognosis in patients with locally
advanced breast cancer (LABC) (Hortobagyi et al, 1994). The
many studies performed to date are, however, different in patient
population studied, local therapy applied and chemotherapy
scheme used. This makes it difficult to compare results and the
optimal treatment scheme still has to be established. In stage I and
II breast cancer, clinical and pathological variables have prog-
nostic significance and are used as a guide for adjuvant therapies
(Carter et al, 1989). Biological characteristics such as nuclear
accumulation of mutant p53, microvessel density (MVD) and
tumour cell proliferation are being used increasingly to further
refine our ability to predict the prognosis of patients with early
breast cancer (Weidner et al, 1991; Isola et al, 1992; Allred et al,
1993; Railo et al, 1993; Gasparini et al, 1994a). Recently, we
reported that the expression of P-glycoprotein (P-gp), may be
indicative ofa worse prognosis in primary stage I-II breast cancer
(Linn et al, 1995). Much less is known regarding these prognostic
factors in LABC. This paper reports the preliminary results of a
prognostic factor analysis on a group of women treated with
neoadjuvant chemotherapy for LABC, incorporating both tradi-
tional and more recently developed factors.
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PATIENTS AND METHODS
Patients
Patients with stage IHA and stage IIIB breast cancer according to
the AJCC criteria (Beahrs et al, 1993) were enrolled into a study
with neoadjuvant doxorubicin 90 mg m-2 and cyclophosphamide
1000 mg m-2 (Pinedo et al, 1996) and GM-CSF 250 ,ug m-2
(Honkoop et al, 1996). As established in a previous dose-finding
study, a dose reduction of 10% relative to the previous dose level
was applied in cycles 2 and 4 in every patient (Hoekman et al,
1991). Initially, it was the intention to give four to six cycles,
dependent upon the rapidity of achieving a clinical complete or
nearly complete remission, and the toxicity for the individual
patient. When the study progressed and toxicity appeared tolerable,
we aimed at the administration of six cycles whenever possible.
This decision was based on the fact that gross residual tumour was
often observed at pathological examination of the mastectomy
specimens when fewer cycles were given. In 24 patients an inci-
sional biopsy was performed for diagnosis. In 18 patients, referred
from other hospitals, other diagnostic procedures were performed:
a subclavicular biopsy in nine patients and a fine-needle aspiration
in another nine patients (Honkoop et al, 1997). All patients under-
went mastectomy according to Madden with axillary dissection,
followed by radiotherapy (4005 cGy in 15 fractions to the thoracic
wall, the internal mammary nodes, the axilla and the supraclavic-
ular fossa). No adjuvant chemotherapy or hormones were applied.
Processing of the histological material
The fresh mastectomy specimens orbiopsies were processed using
standard pathological techniques with fixation in 4% buffered
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Table 1 Antibodies used for immunohistochemical staining on paraffin slides
Antibody Directed against Source Mono/polyclonal Host species Dilution
JSB-1 P-glycoprotein (P-gp) Gift from Professor Dr RJ Scheper Monoclonal Mouse 1:50
Amsterdam, the Netherlands
DO-7 Wild type p53 Dako, Glostrup, Denmark Monoclonal Mouse 1:500
Ki-67 Cells not in Go Dako, Glostrup, Denmark Polyclonal Rabbit 1:100
JC70 CD31 Dako, Glostrup, Denmark Monoclonal Mouse 1:40
ER Oestrogen receptor Abbott Diagnostics, Chicago, USA Monoclonal Mouse 1:1
Table 2 Survival of LABC (n = 42) by univariate analysis for prechemotherapy variables
Variable n DFS P P OS P P
2 years (%) (UV) (MV) 2 years (%) (UV) (MV)
Age (years)
.46 19 77 0.12 90 0.09 0.1
>46 23 58 68
Tumour size (cm)
< 9 22 70 0.15 88 0.3
> 9 20 58 80
Stage
IIIA 21 72 0.13 88 0.3
IIIB 21 60 80
Oestrogen receptor
(+) 14 60 0.5 96 0.08 0.3
(-) 25 55 72
Cd3l
Low 12 68 0.2 90 0.8
High 9 78 100
p53
Low 10 68 0.8 92 0.7
High 17 64 82
P-gp
Low 9 60 0.8 100 0.9
High 18 64 88
Ki-67
Low 13 66 0.9 92 0.9
High 14 64 82
P-gp/p53
Positive 11 38 0.006 0.04 52 0.003 0.04
Negative 17 82 100
*Not included in multivariate analysis. UV, univariate analysis; MV, multivariate analysis.
formaldehyde. Sections (4 ,um thick) were cut and stained with
haematoxylin and eosin (H&E). Antibodies used for immuno-
histochemical staining are listed in Table 1. Staining for Ki-67,
p53, CD31 and P-gp was carried out on formalin-fixed, paraffin-
embedded pre- and post-chemotherapy material. Staining for
CD31 was onlyperformed onprechemotherapy breastbiopsies but
not on infraclavicularbiopsies. The avidin-biotin immunoperoxi-
dase method (van der Valk et al, 1990; Linn et al, 1995) was used,
and a microwave antigen retrieval technique was applied (Shi etal,
1991). Samples were considered positive for P-gp if 2 20% of
tumour cells were stained (Schneider et al, 1989) and positive for
p53 if at least 1% of tumour cell nuclei were stained with DO-7
(Thor et al, 1992). Oestrogen receptor staining was performed on
frozen sections according to the manufacturer's protocol. The
histoscore was applied and the receptor was considered positive
when the score was >100 (Bosman etal, 1992). Microvessels were
counted at 400 magnification using a 40x objective in one area
(consisting of four fields, diameter 0.445 jm) with the highest
MVD at low magnification ('hot spot') (Weidner et al, 1991).
Definition of pathological response
Pathological response was graded as complete (PCR) if no
residual tumour was found in the mastectomy specimen oraxillary
lymph nodes; microscopic when macroscopic examination was
normal but scattered foci of tumour were visible on microscopy
(MPR); macroscopic when tumour was seen macroscopically; and
diffuse when no tumour was seen microscopically but there was
extensive infiltration on microscopic examination. Patients with
PCR and MPR were regarded as one group having minimal
residual disease (MRD), the other patients were regarded as
having gross residual disease (GRD) (Honkoop et al, 1997).
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Table 3 Survival of LABC (n = 42) by univariate analysis for post-chemotherapy factors
Variable n DFS P P OS P P
2 years (%) (UV) (MV) 2 years (%) (UV) (MV)
Number of cycles
<4
5
6
Clinical response
CR
PR
SD
Pathological response
Minimal/no tumour
Gross residual tumour
Axillary nodes
(+)
(-)
Axillary nodes
0
1-3
4-9
2 10
Oestrogen receptor
(+)
(-)
CD31
Low
High
p53
Low
High
P-gp
Low
High
Ki-67
Low
High
P-gp/p53
Positive
Negative
CR, complete remission; PR, partial remission; SD, stable disease; NR, not reliable due to only one patient in this group. aTrend test across the groups.
Prognostic factor analysis and statistics
Clinical and pathological variables included in prognostic signifi-
cance analysis for disease-free survival (DFS) and overall survival
(OS) are listed in Tables 2 and 3. For statistical analysis, grouping
was performed using logical categories for the discrete variables.
For continuous variables the cut-off was the median value (except
for P-gp and p53 as mentioned above). Kaplan-Meier curves were
plotted and differences analysed using the Mantel-Cox test. P-
values below 0.05 were considered significant. Multivariate
analysis of prognostic variables was performed using the Cox
regression model with the limit to enter a variable in the analysis
being set at P < 0.1. All tests were carried out with the Biomedical
Package (BMDP, Statistical Solutions, Cork, Ireland).
RESULTS
The pretreatment characteristics of the patients are shown in Table 4.
As per the initial protocol 18 patients received less than six cycles;
fivepatients receivedfourcycles and 13 patients received fivecycles.
Although the sample sizes were small for the different groups, there
seemed to be no differences in the pretreatment characteristics of
patients who received more than fourcycles, five cycles or six cycles
as in all groups stage IRA and stage HIIB were equally represented
(datanot shown). Theclinical response rate was98% with 21 patients
having a clinical complete response, 20 patients having a partial
response and onepatientwith stabledisease. Pathological andclinical
response is depicted in Table 5. Fifteen patients have relapsed and
eight patients have died with a median follow-up from start of
therapy of 32 months (range 10-72 months). The median time to
progression from start of therapy was 17 months (range 10-30
months). Figure 1 shows OS andDFS forthe whole groupofpatients.
Univariate analysis
Table 2 and Table 3 show OS and DFS at 2 years for pre-
chemotherapy and postchemotherapy variables respectively. Of
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5
13
24
0
55
78
21
20
1
0.003
64
58
NR
32
73
95
0.009
23
19
0.03
80
45
90
72
NR
0.7
24
18
18
8
13
1
54
80
80
68
48
NR
0.05 0.04
0.14
10
23
0.0007a
0.8
0.03
0.05
0.02a
0.7
0.7
0.5
0.8
0.03
0.03
75
66
0.04 0.05
0.04
0.05
0.04
0.008
0.05
94
68
70
94
94
80
62
NR
90
78
82
79
84
64
84
74
82
58
40
100
17
14
15
16
13
17
25
5
12
16
60
68
52
48
54
56
64
20
23
70
0.1
0.8
0.17
0.5
0.08
0.008
NS
0.04
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Table 4 Patient characteristics before treatment
Total number of patients
Age (years), median (range)
Clinical stage
IIIA
IIIB
Inflammatory breast cancer
Tumour diameter (cm) median (range)
Axillary lymph node involvement (clinical)
Number of chemotherapy cycles
<4
5
6
Primary tumour histologya
Ductal
Lobular
Medullary
Papillary/mucinous
Ductal/mucinous
100
42
46 (26-63)
21
21
11
9 (5-15)
35
80
0)
c
'6 60 m
0
a) 40 0
if
20
5
13
24 0
at risk 4 27
3
1
1
1
) 10 20 30 40
months
42 42 31 21 9
42 31 18 10 5
50 60 70 80
4
2
2
2
2
Figure 1 Overall survival (-) and disease-free survival (...) for all patients
aNine cases only preoperative cytology.
Table 5 Clinical and pathological response
Pathological response Number CCR CPR CSD
of patients
No residual tumour 6 5 1
Minimal microscopic tumoura 17 11 6
Diffuse microscopic tumour 6 1 5
Macroscopic tumour 13 4 8 1
Axillary lymph nodes
Negative 18 14 4
1-3 positive 8 4 3 1
4-10 positive 15 3 12
>10 positive 1 0 1
Apical node positive 8 1 7
aThree patients had only very few tumour cells in one lymph node. CCR,
clinical complete response; CPR, clinical partial response; CSD, clinical
stable disease.
the pretreatment factors only one variable appeared to predict
either DFS and/or OS (co-expression of P-gp and p53, P = 0.006
for DFS and P = 0.003 for OS) and only two had a P-value < 0.1
for OS (age, P = 0.09; oestrogen receptor, P = 0.08). An analysis
of postchemotherapy variables revealed that patients who had
received more chemotherapy cycles (P = 0.0007), those with
MRD (P = 0.03), co-expression ofP-gp/p53 (P = 0.03), low Ki-67
staining (P = 0.03), and negative axillary lymph nodes (P = 0.05)
had a more favourable DFS, whereas only the first three factors
were predictive for a better 2 year OS (P = 0.009, P = 0.05 and
P = 0.04 respectively). There was also a significant trend forbetter
DFS (P = 0.02) and better OS (P = 0.04) in patients with fewer
positive lymph nodes at pathological examination. There was no
difference in DFS and OS for patients with PCR compared with
patients who had MPR, and these two factors were, therefore,
combined in the prognostic factor analysis.
Multivariate analysis
The Cox regression analysis revealed the number ofchemotherapy
cycles (P = 0.003), pathological response (P = 0.04), co-expres-
sion of P-gp and p53 pre- and post-chemotherapy (P = 0.04 and
P = 0.05 respectively) and lymph node status at pathological
examination (P = 0.05) to be independent prognostic factors for
DFS, whereas only the first three variables were independent
predictors for OS (P = 0.03, P = 0.04 and P = 0.04 respectively).
When multivariate analysis was carried out with the actual number
of positive lymph nodes at pathological examination, this was an
independent prognostic factor for DFS as well as for OS. A multi-
variate analysis was carried out both with and without Ki-67
staining post chemotherapy and coexpression of P-gp/p53 post
chemotherapy because these factors were only measurable in
patients with residual disease after chemotherapy. When included
in this analysis, Ki-67 staining post-chemotherapy (P = 0.008), co-
expression of P-gp/p53 post-chemotherapy (P = 0.05) and the
number of chemotherapy cycles proved to be the most discrimi-
nant prognostic factors for DFS but the former was not an
independent prognostic factor for OS.
DISCUSSION
The aim ofthis study was to identify clinical and biological factors
with prognostic significance for DFS and OS in patients with
LABC treated with a multidisciplinary approach. The follow-up
time is approaching 3 years, and the median time to progression is
17 months, so webelieve thatthis is longenough to allow sufficient
events to have occurred to make a preliminary analysis ofputative
prognostic factors valid. An important prognostic factor was the
number ofchemotherapy cycles administered. Because the groups
ofpatients receiving different numbers ofcycles were not random-
ized, these results should be interpreted with caution, but the differ-
ences in OS and DFS were highly significant and this at least
suggests that the duration of chemotherapy is important. This
underlines the need for further investigation of optimal treatment
duration in this disease setting. The magnitude of pathological
response, and the presence of involved axillary lymph nodes at
pathological examination were also important prognostic factors.
Earlier, Feldman and colleagues (1986) reported on the prognostic
significance of pathological response after neoadjuvant chemo-
therapy in LABC patients, whereas others (McGready et al, 1989;
Gardin et al, 1995) have stressed the importance of lymph node
metastases after neoadjuvant chemotherapy in LABC patients.
Certainly, the attainment ofapathological complete remission is an
important measure ofthe efficacy ofneoadjuvant chemotherapy, as
attested by data from patients with osteosarcoma (Rosen et al,
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1982). Proliferation as measured by Ki-67 staining did not have
prognostic significance in the pretreatment biopsies, which is in
contrast to most studies in earlier breast cancer (Railo et al, 1993;
Gasparini et al, 1994b). Patients with a higher proliferation after
chemotherapy as measured by Ki-67 staining had shorter DFS and
OS. This may indicate that this primary tumour variable reflects the
proliferative capacity ofthe micrometastases that ultimately deter-
mines the prognosis. Other biological variables such as nuclear
accumulation ofp53 (Isola etal, 1992; Allred etal, 1993; Gasparini
et al, 1994a; Rosen et al 1995), MVD (Weidner et al, 1991;
Gasparini et al, 1994a) or P-gp staining (Linn et al, 1995), which
have been suggested to be of importance in stages I and II breast
cancer, were not significant in this study (P-values all > 0.1). Riou
et al (1993) studied the prognostic significance ofnuclear accumu-
lation of p53 in 24 patients with inflammatory breast cancer, and
they observed a worse prognosis forpatients with nuclear accumu-
lation of p53. Earlier we have reported that co-expression of P-gp
and p53 were indicative of a worse prognosis in LABC patients
(Linn et al, 1996), and this remained so in this slightly larger group
of patients. Expression of one of these factors did not have prog-
nostic significance. The failure of MVD to be of significance may
well berelated to the factthatthese tumours areofa more advanced
stage compared with stage I breast cancer.
In conclusion, biological markers such as p53, P-gp, MVD and
Ki-67, determined in this small group of LABC patients treated
with multidisciplinary therapy, did not seem to have theprognostic
importance that they possess in early-stage breast cancer. The co-
expression of P-gp and p53 was, however, predictive of a poor
prognosis. It is possible that with a larger sample size significant
differences might become apparent. It is, however, also possible
that because of the advanced stage of these tumours micrometas-
tases had already occurred in the majority, if not all, of these
patients. In this situation, the outcome may well be determined by
biological characteristics of tumour cells in the metastases and be
less influenced by the characteristics of the primary tumour. Only
with a larger series ofpatients would it be possible to resolve this
question. Furthermore, it appears that attainment of a complete
pathological response is of importance in this disease. The proba-
bility thatthis will occurmightbeenhanced by extending the dura-
tion ofchemotherapy, as this was an important factor in this study.
Alternatively, regimens with greaterefficacy in breast cancer, such
as those containing taxanes, vinorelbine or dose intensification,
would be worth exploring in this setting. A larger study with
longer follow-up is needed to confirm these conclusions.
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